Case report
In 30-year-old Caucasian man was referred to our Center for a ten-year
history of maculopapular rash, intractable itching, flushing and a
six-month history of diarrhea (3-4 bowel movements per day with loose
stools associated to a <10% weight loss). The medical history
was otherwise unremarkable, except for a non-steroidal anti-inflammatory
drug-induced anaphylaxis.
Complete blood count, common coagulation, liver and renal function tests
were in a normal range. A computed tomography (CT) scan showed diffuse
lymphadenopathy (up to ) and mild hepatosplenomegaly. The screening
serum tryptase level was 209 ng/ml (normal level <5 ng/ml).
Gastric, duodenal, distal ileal and colonic biopsies revealed a diffuse
mucosal mast cell infiltration, with abnormal expression of CD2 and
CD25, compatible with SM diagnosis. An abdominal lymph node biopsy also
confirmed the SM diagnosis and excluded a lymphoproliferative disease.
At bone marrow biopsy multifocal clusters of spindling mast cells CD25+
were equal to 70% of total cellularity. Aspirate smears showed
<5% of mast cells and a direct sequencing of the KITgene was positive for the D816V mutation. A total skeleton X-ray was
negative for a bone lytic or sclerotic involvement, while osteoporosis
was diagnosed on the basis of reduced bone mineral density at
dual-energy X-ray absorptiometry scan for which calcium/vitamin D
supplements were started. Since the patient presented only B-findings,
diagnosis of SSM was made and he was not considered a candidate for a
cytoreductive treatment. The patient was instructed to avoid triggers of
MC degranulation and therapy with H1-H2 histamine receptor blockers;
sodium cromolyn was started with a symptomatic purpose for itching and
diarrhea obtaining a good control.
During the follow-up, patient’s general conditions slowly worsened with
the appearance of a pathological weight loss (>10%), a
more severe diarrhea and a progressive enlargement of abdominal lymph
nodes, liver and spleen. In April 2017 confluent abdominal
lymphoadenopathy had a maximum diameter of 6 cm, conditioning appearance
of ileal dislocation and ascites due to SM liver involvement
(histologically confirmed). Liver and spleen had a diameter of 24 and 17
cm, while bone marrow involvement remained unchanged as for biopsy and
morphology. Blood count was normal and serum tryptase level raised to
332 ng/ml. We concluded for aggressive evolution of SM. First line
cytoreductive therapy was started in April 2017 with subcutaneous
cladribine 0,14 mg/Kg per day for 5 days per cycle. A total of 5 cycles
every 6 weeks were administered. Therapy was overall well tolerated and
no grade 3/4 hematologic toxicities were observed. By the end of the
fifth cycle the disease had not yet reached a response with persistence
of symptoms, 60% of MC involvement at bone marrow biopsy, and stable
lymphadenopathy and hepatosplenomegaly. Serum tryptase level was 173
ng/ml.
From December 2017 midostaurin was obtained through an expanded access
use and started at a dosage of 25 mg twice daily, gradually increased to
100 mg every 12 hours.
Rapidly after starting midostaurin, the patient experienced a
considerable improvement of general condition, clinical symptoms and
body weight. After 3 months of midostaurin therapy, a bone marrow biopsy
highlighted the reduction of MC infiltration to 30-40%, lymphadenopathy
decreased to a diameter of 27 mm, hepatic and splenic diameter were 22
and 13 cm. Serum tryptase was 26 ng/ml. Unfortunately, the CT scan
allowed to incidentally diagnose a subclinical pulmonary embolism of a
segmental artery in the superior left lobe. Pulmonary embolism is
reported among adverse events during midostaurin treatment, therefore we
stopped the TKI treatment and start anticoagulant therapy. Midostaurin
was safely resumed one month later; evaluation at 6 month showed only
10% of MC in the bone marrow biopsy and further reduction of
lymphadenopathy to a maximum diameter of 22 mm. Figure 1 and2 respectively show the reduction of bone marrow MCs infiltrate
and organomegaly over time.
Today the patient is still on midostaurin 100 mg bid, completely
asymptomatic and with good tolerance to the therapy. A human leukocyte
antigen typing was performed, but allogeneic stem cell transplant isn’t
currently taken consideration. At the last assessment (February 2020)
maximum diameter of abdominal lymphadenopathy and spleen were 1.5 and 13
cm, serum tryptase level was 27 ng/ml and bone marrow MCs have
stabilized on 10% of the global cellularity. The response was
classified as partial according to Gotlib et al. [11]
For the clinical management of a SM patient the most relevant questions
are whether the patient has or develops advanced SM and what treatment
can be applied. Although the risk is relatively low, patients with ISM
may progress to ASM, SM-AHNMD or MCL. [1-5]
Here, we report the gradual evolution of a SSM case in ASM, conditioning
hepatomegaly with impairment of liver function and ascites, splenomegaly
and abdominal lymphoadenopathy with ileal dislocation.
According to the current guidelines, ISM therapy is generally focused on
symptom relief. [3,4] All patients should be advised to avoid any
potential triggers (food, drinks, drugs) that may provoke MCs
activation. High risk patients are advised to carry epinephrine
self-injector-pens. Treatment options include histamine H1/H2-blockers,
sodium cromolyn, leukotriene inhibitors, topical agents, aspirin,
ketotifen, omalizumab, corticosteroids and MC cytoreductive therapy only
in severe/refractory cases. [3,4] In our case, during the smoldering
phase, the patient received H1-H2 histamine receptor blockers and sodium
cromolyn for itching and diarrhea obtaining a good control.
When an aggressive phase was diagnosed, considering the burden of the
disease and the absence of comorbidities, we decided to offer a
cytoreductive treatment with cladribine. MC reducing therapy is
indicated in advanced SM to prevent further organ damage, extend
survival, often at the expense of significant side effects. [6,7]
Cladribine was one of the first agent used for symptom relief and rapid
MC debulking, with a demonstrated therapeutic activity in all SM
subtypes and an overall response rate (ORR) of 50-60%. [6,7]
Myelosuppression and lymphopenia are the most frequent adverse events.
[6,7] In our case cladribine was well tolerated without grade 3/4
toxicities. With the advent of KIT -targeted TKIs, the use of
cytoreductive therapy has declined. [3,4] The multikinase inhibitor
midostaurin is currently approved for patients with advanced SM. In this
population it demonstrated a 60% ORR and a good tolerability with few
reported adverse events apart from hematological toxicity, nausea, vomit
and diarrhea. [8]
Our patient received midostaurin after failure of first-line therapy
with cladribine. Midostaurin lead to a significant improvement of
organomegaly, liver function and body weight; moreover a substantial
reduction in MC burden and mediator-related symptoms were observed,
translating into a significant amelioration of patient’s life quality.
This treatment is still ongoing, with almost 2 years of therapy,
allowing to obtain and keep a partial response.
In conclusion, mastocytosis is a rare disease with a complex biology and
an unpredictable clinical course. The diagnosis and management of MC
neoplasms is an emerging challenge and requires vast knowledge, a
multidisciplinary diagnostic approach and personalized treatment
strategy.
Disclosure Statement : FIG received compensation by Novartis as
expert testimony and as a member of advisory board. The remaining
authors declare no conflict of interest.
Author Contribution : MS, FS, MCG, GNS, GG, LB, FO and FIG
provided the patient data regarding the hematological disease; MS, FS
and FIG wrote the manuscript; SM, VP and FMU provided patient data for
what concerns dermatological, allergological and rheumatological
aspects; GAC performed the histological examinations of bone marrow,
provided iconographic materials, interpreted these data and integrated
them in the manuscript; ACM revised patient peripheral blood smears; AE
provided radiological iconographic material. All authors critically read
and approved the final manuscript.